1 active not recruiting, 1 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Biorasi, Llc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study in Subjects With Mild-to-Moderate Alzheimer's Dementia ALZN002 (autologous DCs pulsed with E22W mutant peptide)., Placebo - Alzheimer Disease | Phase 1 / Phase 2 | Active not recruiting | Alzamend Neuro, Inc. | 30 | 2023-07-05 | 2026-09-30 |
| Bio-equivalence Study Between SAPHRIS and Asenapine SAPHRIS, Asenapine - Schizophrenia, Bipolar Disorder | Phase 1 | Completed | Sun Pharmaceutical Industries Limited | 65 | 2013-07-01 | 2021-04-30 |
Alzheimer Disease (1) · Bipolar Disorder (1) · Schizophrenia (1)
asenapine (1)
United States (2)
David Walling, MD (1) · Evagelos Coskinas, MD (1) · Gilbert R. Weiner, DO (1) · James S. McDonough, MD (1) · Jim G. Aukstuolis, MD (1) · Kurian Abraham, MD (1) · Robert A Riesenberg, MD (1)